Oncofetal protein IMP3: a useful diagnostic biomarker for leiomyosarcoma
Human Pathology, 04/13/2012
Cornejo K et al. – The expression of IMP3 in both uterine and soft tissue leiomyosarcomas can be used as a positive biomarker to increase the level of confidence in establishing a definitive diagnosis of a malignant smooth muscle tumor.
A total of 216 cases (resection, n = 183; biopsy, n = 33) consisting of 82 leiomyosarcomas (uterine, n = 15; soft tissue, n = 67), 62 leiomyomas (uterine, n = 50; soft tissue, n = 12), and 72 uterine-variant leiomyomas (atypical, n = 19 [14%]; cellular, n = 21 [16%]; mitotically active, n = 12 [9%]; myxoid, n = 11 [8%]; vascular, n = 3 [2%]; epithelioid, n = 1 [1%]; benign metastasizing, n = 1 [1%]; and smooth muscle tumors of uncertain malignant potential, n = 4) were examined by immunohistochemistry for IMP3 expression.
IMP3 showed strong cytoplasmic staining in 43 (52%) of 82 leiomyosarcomas, regardless of histologic grades.
There was no difference in IMP3 expression between uterine and soft tissue leiomyosarcomas.
In contrast to malignant tumors, IMP3 expression was not found in any of the typical leiomyomas (0/62 cases).
All uterine-variant leiomyomas were negative, except for 3 cases (atypical variant, n = 2; cellular variant, n = 1) for IMP3 staining.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.